SCHEMBL278453

SCHEMBL278453

CCOC(=O)c1ccc(C(=O)NN2CCCCC2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.49
HDAC4 P56524 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
LMNA P02545 3/20 0.46
KMT2A Q03164 2/20 0.46
MAPK1 P28482 2/20 0.46
NR3C1 P04150 2/20 0.44
AR P10275 2/20 0.44
HTT P42858 2/20 0.43
ALDH1A1 P00352 5/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HPGD P15428 3/20 0.41
KDM4E B2RXH2 2/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.41
CASP3 P42574 1/20 0.41
SENP7 Q9BQF6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5269934 0.86 MAPK1 (0.50) LMNAKMT2AMAPK1HTTALDH1A1
SCHEMBL279935 0.80 KMT2A (0.54) LMNAKMT2AMAPK1HTTALDH1A1
SCHEMBL277005 0.80 HTT (0.50) LMNAKMT2AMAPK1HTTALDH1A1
SCHEMBL12313814 0.79 ALDH1A1 (0.60) LMNAKMT2AMAPK1HTTALDH1A1
SCHEMBL7018973 0.77 HDAC3 (0.73) HDAC3HDAC4HDAC1HDAC6LMNA
SCHEMBL5224398 0.76 HDAC3 (0.49) HDAC3HDAC4HDAC1HDAC6LMNA
SCHEMBL5227048 0.74 HDAC3 (0.50) HDAC3HDAC4HDAC1HDAC6LMNA
SCHEMBL8177110 0.74 HRH3 (0.55) HDAC3HDAC4HDAC1HDAC6LMNA
SCHEMBL12265884 0.73 YEATS4 (0.60) LMNAKMT2AMAPK1HTTALDH1A1
SCHEMBL277132 0.73 KMT2A (0.68) HDAC6LMNAKMT2AMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL HDAC3 1355/4885HDAC4 2541/4885HDAC1 1145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.